Source: Eur Respir J 2016; 48: 1271-1273



Rating:

Share or cite this content

Citations should be made in the following way:
Ivan O. Rosas. Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis?. Eur Respir J 2016; 48: 1271-1273

Member's Comments

No comment yet.

Related content which might interest you: N-ethyl-N-nitrosourea mutagenesis: a new tool for exploring lung disease Source: Annual Congress 2010 - Scientific Year in Review Year: 2010 Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate Source: Eur Respir J 2010; 35: 768-775 Year: 2010 Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Validation of a novel prognostic tool for idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019 Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help? Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Fibrocytes: potential new therapeutic targets for pulmonary hypertension? Source: Eur Respir J 2010; 36: 1232-1235 Year: 2010 Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring Source: Eur Respir J 2006; 28: Suppl. 50, 152s Year: 2006 Novel strategy to identify genetic risk factors for COPD severity: genetically isolated populations Source: Annual Congress 2008 - Genetic risk factors for asthma and COPD Year: 2008 Novel imaging biomarkers for assessment of lung fibrosis and inflammation Source: Virtual Congress 2021 – Emerging imaging biomarkers in lung disease Year: 2021 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Proof of concept of a non-invasive screening tool to detect idiopathic pulmonary fibrosis (IPF) in an early stage Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 COPD – will new insights into molecular pathology define new therapies? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 Risk stratification of pulmonary embolism: clinical evaluation, biomarkers or both? Source: Eur Respir J 2015; 46: 1551-1553 Year: 2015 Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort Source: Eur Respir J, 57 (6) 2002591; 10.1183/13993003.02591-2020 Year: 2021 Gene expression profiles of idiopathic interstitial pneumonias: Identification of disease-specific diagnostic markers and molecular therapeutic targets Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012